ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biosimilars"

  • Abstract Number: 2461 • 2017 ACR/ARHP Annual Meeting

    Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study

    Dae-Hyun Yoo1, Won Park2, Chang-Hee Suh3, Seung-Cheol Shim4, Sang-Joon Lee5, Yun Ju Bae5, Chan Park5 and Noo Ri Han5, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), 3Ajou University School of Medicine, Suwon, Korea, Republic of (South), 4Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), 5CELLTRION, Inc., Incheon, Korea, Republic of (South)

    Background/Purpose: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in RA patients.1 However, there are limited…
  • Abstract Number: 2484 • 2017 ACR/ARHP Annual Meeting

    When Etanercept Switch Fails – Clinical Considerations

    Oliver Hendricks and Kim Hørslev-Petersen, King Christian X's Hospital for Rheumatic Diseases, University of Southern Denmark, Institute of Regional Health Research, Denmark, Graasten, Denmark

    Background/Purpose: On January 14th 2016 EMA approved the biosimilar Etanercept (SB4, Benepali) for clinical use. A non-medical switch from originator Etanercept (ETA, Enbrel) to SB4…
  • Abstract Number: 2492 • 2017 ACR/ARHP Annual Meeting

    The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study

    Ingrid Louw1, Alan J. Kivitz2, Tsutomu Takeuchi3, Yoshiya Tanaka4, Satoshi Nakashima5, Jennifer Hodge6, Hong Tang6, Paula O'Connor6 and Barbara Finck6, 1Panorama Medical Centre, Cape Town, South Africa, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 3Keio University School of Medicine, Tokyo, Japan, 4School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 5Daiichi Sankyo, Tokyo, Japan, 6Coherus BioSciences, Inc., Redwood City, CA

    Background/Purpose: CHS-0214 is a proposed biosimilar to etanercept for the treatment of rheumatoid arthritis and other auto-immune diseases. Two randomized, double-blind studies demonstrated equivalence of…
  • Abstract Number: 2795 • 2017 ACR/ARHP Annual Meeting

    Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study

    Hans-Peter Tony1, Hendrik Schulze-Koops2, Klaus Krüger3, Stanley B Cohen4, Alan J. Kivitz5, Slawomir Jeka6, Edit Vereckei7, Liyi Cen8 and Dmitrij Kollins8, 1Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 3Praxiszentrum St. Bonifatius München, München, Germany, 4Metroplex Clinical Research Centre, Dallas, TX, 5Altoona Center for Clinical Research, Duncansville, PA, 62nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, 7National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 8Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany

    Background/Purpose: GP2013, is a biosimilar to European Union (EU) approved reference rituximab (RTX), developed in a stepwise approach that adheres to stringent biosimilar development guidelines.…
  • Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting

    A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis

    Josef S. Smolen1, Stanley B Cohen2, Morton Scheinberg3, Tamas Shisha4, Dmitrij Kollins4, Peijuan Zhu5, Liyi Cen4, Alan J. Kivitz6, Andra Rodica Balanescu7, Juan J. Gomez-Reino8 and Hans-Peter Tony9, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Metroplex Clinical Research Centre, Dallas, TX, 3Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 4Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, 5Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, 6Altoona Center for Clinical Research, Duncansville, PA, 7Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 8BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, 9Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany

    Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…
  • Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting

    Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab

    Lorie A. Ellis1, Ismail Simsek2, Lin Xie3, Adesuwa Ogbomo3, Dennis Parenti4, Kavitha Goyal4 and Yusuf Yazici5, 1Janssen HECOR Immunology, Horsham, PA, 2Guven Hospital, Ankara, Turkey, 3STATinMED Research Inc., Ann Arbor, MI, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5New York University School of Medicine, New York, NY

    Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…
  • Abstract Number: 2797 • 2017 ACR/ARHP Annual Meeting

    Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study

    Arthur Kavanaugh1, Yannick Allanore2, Eugeniusz J. Kucharz3 and Goran Babic4, 1Medicine, University of California, San Diego, La Jolla, CA, 2Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, 3Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland, 4Clinical development, Biopharmaceuticals, Hexal AG, a Sandoz company, Holzkirchen, Germany

    Background/Purpose: The biosimilarity of GP2015 and etanercept originator product (ETN) has been previously demonstrated in patients with chronic plaque-type psoriasis.1 The randomized, double-blind, phase 3…
  • Abstract Number: 1037 • 2017 ACR/ARHP Annual Meeting

    Biosimilar Knowledge Among US Rheumatologists – a Survey

    Allan Gibofsky1,2 and Sam Badawi3, 1Medicine and Public Health, Hospital for Special Surgery, New York, NY, 2Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, 3Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

    Background/Purpose: Four biosimilar tumor necrosis factor α (TNFα) inhibitors have been approved by the FDA in the United States as of April 2017. This survey…
  • Abstract Number: 2798 • 2017 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind Study Comparing PF-06438179/GP1111, a Potential Infliximab Biosimilar, and Infliximab, Both in Combination with MTX, As Treatment for Patients with Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Therapy

    Stanley B Cohen1, Rieke Alten2, Hideto Kameda3, Muhammad I. Rehman4, Karl Schumacher5, Susanne Schmitt5, Steven Y. Hua6 and K. Lea Sewell7, 1Metroplex Clinical Research Center, Dallas, TX, 2Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, 4Pfizer Inc, Andover, MA, 5Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany, 6Pfizer Inc, San Diego, CA, 7Biosimilars Development, Pfizer Inc, Cambridge, MA

    Background/Purpose: This double-blind, randomized study evaluated efficacy, safety and immunogenicity of PF‑06438179/GP1111, a potential infliximab biosimilar, vs infliximab sourced from the EU (infliximab-EU) in patients…
  • Abstract Number: 1041 • 2017 ACR/ARHP Annual Meeting

    Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US

    Janna Radtchenko, Yolaine Smith, Jonathan Kish and Bruce Feinberg, Specialty Solutions, Cardinal Health, Dallas, TX

    Background/Purpose: A biosimilar product is a biological product highly similar to another FDA-approved biological product, reference product, and has no clinically meaningful differences in safety…
  • Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting

    Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)

    Mark C. Genovese1, Josephine Glover2, Nobuhito Matsunaga3, Diane Chisholm4 and Rieke Alten5, 1Stanford University Medical Center, Palo Alto, CA, 2Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, 3Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, 4Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, 5University Medicine Berlin, Berlin, Germany

    Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
  • Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting

    Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway

    Guro Løvik Goll1,2, Inge C Olsen3, Kristin K Jorgensen4, Merete Lorentzen5, Nils Bolstad6, Espen A. Haavardsholm7, Knut EA Lundin8, Cato Mork9, Jorgen Jahnsen4, Tore K Kvien3 and the NOR-SWITCH study group, 1Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, 5Dept of Dermatology, Rikshospitalet, Oslo, Norway, 6Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway, 8Dept of gastroenterology, Rikshospitalet, Oslo, Norway, 9Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

      Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of  spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA),  Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
  • Abstract Number: 604 • 2016 ACR/ARHP Annual Meeting

    Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study

    Michael Weinblatt1, Asta Baranauskaite2, Jaroslaw Niebrzydowski3, Eva Dokoupilova4, Agnieszka Zielinska5, Karina Sitek-Ziolkowska6, Janusz Jaworski7, Artur Racewicz8, Margarita Pileckyte2, Krystyna Jedrychowicz-Rosiak9, Vyacheslav Zhdan10, Soo Yeon Cheong11 and Jeehoon Ghil11, 1Brigham and Women’s Hospital, Boston, MA, 2Lithuanian University of Health Sciences, Kaunas, Lithuania, 3Medica Pro Familia, Gdynia, Poland, 4MEDICAL PLUS s.r.o, Uherske Hradiste, Czech Republic, 5Medica Pro Familia Sp. z o.o. Spolka Komandytowo-Akcyjna, Warszawa, Poland, 6Medica pro Familia, Katowice, Poland, 7Reumatika Centrum Reumatologi, Warszawa, Poland, 8Zdrowie Osteo- Medic s.c, Bialystok, Poland, 9Przychodnia Neuromedyka, Zyrardów, Poland, 10M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine, 11Samsung Bioepis Co., Ltd., Incheon, South Korea

    Background/Purpose: SB5 has been developed as a biosimilar of the reference adalimumab (ADL). The 24-week results of the phase III study have been reported.1 Efficacy,…
  • Abstract Number: 621 • 2016 ACR/ARHP Annual Meeting

    Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis

    Catalin Codreanu1, Klara Sirova2, Katerina Jarosova3 and Anastas Batalov4, 1Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, 2Revmatologie, Revmatologie MU Dr. Klara Sirova, sro, Ostrava, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic, 4Rheumatology, Medical University of Plovdiv, UMHAT Kaspela, Plovdiv, Bulgaria

    Background/Purpose: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, the high…
  • Abstract Number: 622 • 2016 ACR/ARHP Annual Meeting

    Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study

    Mark C. Genovese1, Michael Weinblatt2, Edward C. Keystone3, Asta Baranauskaite4, Soo Yeon Cheong5 and Jeehoon Ghil5, 1Stanford University Medical Center, Palo Alto, CA, 2Brigham and Women’s Hospital, Boston, MA, 3Mount Sinai Hospital, Toronto, ON, Canada, 4Lithuanian University of Health Sciences, Kaunas, Lithuania, 5Samsung Bioepis Co., Ltd., Incheon, South Korea

    Background/Purpose : SB5 has been developed as a biosimilar of the reference adalimumab (ADL). The 52-week efficacy and safety results were reported previously. 1 Here…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology